Catheter composition and uses thereof

• US 7,829,082 B2
• Filed: 06/23/2006
• Issued: 11/09/2010
• Est. Priority Date: 11/26/2001
• Status: Expired due to Term

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Semba, Charles P.
• Primary Examiner(s): Rao; Manjunath N
• Assistant Examiner(s): Tsay; Marsha M.
• Application Number:
  US11/426,263
• Publication Number:
  US 20060246050A1
• Time in Patent Office: 1,600 Days
• Field of Search: 604/53, 604/508, 435/69.1, 435/94.63
• US Class Current: 424/94.63
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/49 Urokinase; Tissue plasminogen activator
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

A composition useful for removal of fibrin-bound blood clots from a catheter comprises water, a fibrinolytically effective amount of a plasminogen activator, and a preservatively effective amount of a bacteriostatic organic alcohol. The composition does not comprise a chelating agent.

Claims

1. A method for removing fibrin-bound blood clots from a catheter that contains such blood clots comprising contacting the catheter for at least about 5 days with a composition comprising water, a fibrinolytically effective amount of a tissue-plasminogen activator in a native form (t-PA) or in a variant form selected from group consisting of reteplase and tenecteplase, and a preservatively effective amount of a bacteriostatic organic alcohol, wherein the composition does not comprise a chelating agent.

2. The method of claim 1 wherein the catheter is contacted with the composition for about 6 to 15 days.

3. The method of claim 1 wherein the tissue-plasminogen activator is in the native form (t-PA).

4. The method of claim 1 wherein the organic alcohol is benzyl alcohol.

5. The method of claim 1 wherein the fibrinolytically effective amount of tissue-plasminogen activator is from about 0.1 to 10 mg/mL and the preservatively effective amount of organic alcohol is from about 0.5 to 1.2% (v/v).

6. The method of claim 5 wherein the fibrinolytically effective amount of tissue-plasminogen activator is from about 0.3 to 4 mg/mL.

7. The method of claim 1 wherein the water in the composition is bacteriostatic water for injection or bacteriostatic normal saline.